Spotlight on enoxaparin in ST-segment elevation myocardial infarction

Area of Science:

• Cardiology
• Pharmacology

Background:

• ST-segment myocardial infarction (STEMI) management traditionally uses unfractionated heparin (UFH).
• Low-molecular-weight heparin (LMWH) like enoxaparin offers potential advantages in pharmacodynamics and efficacy.
• Enoxaparin is FDA-approved for medically managed STEMI and STEMI with percutaneous coronary intervention.

Purpose of the Study:

• To compare the efficacy and safety of enoxaparin versus UFH in STEMI patients undergoing fibrinolytic therapy.
• To evaluate the long-term clinical outcomes and net clinical benefit of enoxaparin in STEMI management.

Main Methods:

• The ExTRACT-TIMI 25 trial compared enoxaparin with UFH in STEMI patients.
• Patients received enoxaparin via intravenous bolus followed by subcutaneous injections, with dose adjustments for age and renal function.
• Primary endpoint: 30-day incidence of all-cause mortality plus recurrent nonfatal myocardial infarction (MI).

Main Results:

• Enoxaparin was significantly more effective than UFH in reducing the primary endpoint at 30 days and maintained this benefit at 1-year follow-up.
• A secondary endpoint, including urgent revascularization, also showed significant improvement with enoxaparin.
• Enoxaparin was associated with a higher incidence of bleeding but demonstrated a net clinical benefit over UFH.

Conclusions:

• Enoxaparin is a more effective antithrombotic agent than UFH for STEMI patients treated with fibrinolysis.
• Despite increased bleeding risk, enoxaparin provides a net clinical benefit, supporting its use in STEMI management.
• Specific dosing guidelines for elderly patients and those with renal impairment are crucial for enoxaparin therapy.